Retinal vein occlusion: Genetic predisposition and systemic risk factors

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 3, 2013, Pages 279-283

  Giannaki, Kassiani ^a   Politou, Marianna ^a   Rouvas, Alexandros ^b   Merkouri, Efrossyni ^a   Travlou, Anthi ^a   Theodosiadis, Panayiotis ^b   Gialeraki, Argyri ^a  

^a Haematology Laboratory   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

diabetes; dyslipidemia; hypertension; retinal vein occlusion genetic markers; thrombophilia

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GREECE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; RISK ASSESSMENT; SMOKING; THROMBOPHILIA;

AGED; AGED, 80 AND OVER; BLOOD COAGULATION FACTORS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETINAL VEIN OCCLUSION; RISK FACTORS;

EID: 84875829883     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32835bfda1     Document Type: Article

References (41)

1. Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophisiol Haemost Thromb 2002; 32:308-311. (Pubitemid 37490559)
2. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophtalmol 1996; 114:545-554.
3. Hayreh SS, Zimmermann B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131:61-67.
4. David R, Zangwill L, Badarna M, Yassur Y. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 1988; 197:69-74.
5. Dodson PM, Kubicki AS, Taylor KG, Kritzinger EE. Medical conditions underlying recurrence of retinal vein occlusion. Br J Ophthalmol 1985; 69:493-496. (Pubitemid 15069218)
6. Arend O, Renky A, Jung F, Kiesewetter H, Reim M, Wolf S. Role of rheologic factors in patients with acute central retinal vein occlusion. Ophthalmology 1996; 103:80-86. (Pubitemid 26046163)
7. Recchia FM, Carvalho-Recchia CA, Hassan TS. Clinical course of younger patients with central retinal vein occlusion. Arch Ophthalmol 2004; 122:317-321. (Pubitemid 38314190)
8. Politou M, Gialeraki A, Merkouri E, Travlou A, Baltatzis S. Central retinal vein occlusion secondary to clomiphene treatment in a male carrier of Factor V Leiden. Genetic Testing Molec Biomarkers 2009; 13:155-157.
9. Kuhli-Hattenbach C, Scharrer I, Ló chtenberg M, Hattenbach L-O. Coagulation disorders and the risk of retinal vein occlusion. Thromb Haemost 2010; 103:299-305.
10. Marcucci R, Bertini L, Giusti B, Brunelli T, Fedi S, Cellai AP, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001; 86:772-776. (Pubitemid 32834184)
11. Ilhan F, Celiker U, Godekmerdan A, Kan E. The antiphospholipid antibody syndrome research in patients with retinal venous occlusion. Med Res 2005; 36:372-375. (Pubitemid 40798391)
12. Biancardi A-L, Gadelha T, Inturias W, Borges S, Vieira de Moraes H, Spector N. Thrombophilic mutations and risk of retinal vein occlusion. Arq Bras Ofthalmol 2007; 70:971-974.
13. Vine AK. Hyperhomocysteinemia: a new risk factor for central retinal vein occlusion. Trans Am Ophthalmol Soc 2000; 98:493-503. (Pubitemid 32059520)
14. Appiah AP, Trempe CL. Risk factors associated with branch vs. central retinal vein occlusion. Ann Ophtalm 1989; 21:153-157.
15. Hayreh SS, Zimmerman MG, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994; 117:429-441. (Pubitemid 24115701)
16. Williamson TH. Central retinal vein occlusion: what's the story? Br J Ophthalmol 1997; 81:698-704. (Pubitemid 27429939)
17. Turello M, Pasca S, Daminato R, Dello Russo P, Giacomello R, Venturelli U, et al. Retinal vein occlusion: evaluation of 'classic' and 'emerging' risk factors and treatment. J Thromb Thromb 2010; 29:459-464.
18. Sodi A, Giambene B, Marcucci R, Sofi F, Fedi S, Abbate R, et al. Atherosclerotic and thrombophilic risk factors in patients with ischemic central retinal vein occlusion. Retina 2011; 31:724-729.
19. Rehak M, Krcova V, Slavik L, Fric E, Langova K, Ulehlova J, Rehak J. The role of thrombophilia in patients with retinal vein occlusion and no systemic risk factors. Can J Ophthalmol 2010; 45:171-175.
20. Rehak M, Rehak J, Mueller M, Faude S, Faude F, Siegemund A, et al. The prevalence of activated protein C resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis. Thromb Haemost 2008; 99:925-929. (Pubitemid 351705310)
21. Gialeraki A, Politou M, Rallidis L, Merkouri E, Markatos C, Kremastinos D, et al. Prevalence of prothrombotic polymorphisms in Greece. Genet Test 2008; 12:541-547.
22. Larsson J, Hillarp A, Olafsdottir E, Bauer B. Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta Ophthalmol Scand 1999; 77:634-637. (Pubitemid 30006802)
23. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93:1021-1026. (Pubitemid 40823503)
24. de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000; 83:577-582. (Pubitemid 30201134)
25. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb Haemost 2009; 102:360-370.
26. Albisinni R, Coppola A, Loffredo M, Cerbone AM, Di Minno G, Greco GM. Retinal vein occlusion and inherited conditions predisposing to thrombophilia. Thromb Haemost 1998; 80:702-703. (Pubitemid 28479363)
27. Sottilotta G, Oriana V, Latella C, Luise F, Piromalli A, Ramirez F, et al. Role of hyperomocysteinemia in retinal vascular occlusive disease. Clin Appl Thromb Haemost 2007; 13:104-107. (Pubitemid 44905287)
28. Cruciani F, Moramarco A, Curto T, Labate A, Recupero V, Conti L, et al. MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion. Clin Ter 2003; 154:299- 303. (Pubitemid 44897494)
29. McGimpsey SJ, Woodside J, Bamford L, Graydon R, Gilchrist S, Young IS, et al. Retinal vein occlusion, homocysteine and methylene tetrahydrofolate reductase genotype. Invest Ophthalmol Vis Sci 2005; 46:4712-4716. (Pubitemid 44264574)
30. Tsantes AE, Nikolopulos GK, Bagos PG, Bonavas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 2005; 122:736- 742.
31. Gori AM, Marcucci R, Fatini C, Gensini F, Sticchi E, Sodi A, et al. Impaired fibrinolysis in retinal vein occlusion: a role of genetics determinants of PAI-1 levels. Thromb Haemost 2004; 92:54-60. (Pubitemid 39010867)
32. Glueck CJ, Wang P, Bell H, Rangaraj V, Goldenberg N. Association of thrombophilia, hypofibrinolysis and retinal vein occlusion. Clin Appl Thromb Haemost 2005; 11:375-389. (Pubitemid 41546764)
33. Bagoly Z, Koncz Z, Há rsfalvi J, Muszbek L. Factor XIII, clot structure, thrombosis. Thromb Res 2012; 129:382-387.
34. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12:135-145.
35. Medina P, Navarro S, Estellé s A, Espan? a F. Polymorphisms in the endothelial protein C receptor gene and thrombophilia. Thromb Haemost 2007; 98:564-569. (Pubitemid 47412882)
36. von Depka M, Czwalinna A, Eisert R, Wermes C, Scharrer I, Ganser A, et al. Prevalence of a 23 bp insertion in exon 3 of the endothelial cell protein C receptor gene in venous thrombophilia. Thromb Haemost 2001; 86:1360- 1362. (Pubitemid 34007504)
37. Saposnik B, Reny JL, Gausem P, Emmerich J, Aiach M, Gandrille S. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 2004; 103:1311-1318. (Pubitemid 38168642)
38. Medina P, Navarro S, Estellé s A, Vayá A, Woodhams B, Mira Y, et al. Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial proteinC receptor and circulating activated protein C levels and thrombotic risk. Thromb Haemost 2004; 91:905-911. (Pubitemid 38647493)
39. Medina P, Navarro S, Estellé s A, Vayá A, Bertina RM, Espan?a F. Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden. Thromb Haemost 2005; 94:389-394. (Pubitemid 41122494)
40. Uitte de Willige S, Van Marion V, Rosendaal FR, Vos HL, de Visser MC, Bertina RM. Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J Thromb Haemost 2004; 2:1305-1310. (Pubitemid 40186125)
41. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149:209